{"doi":"10.1111/epi.17431","title":"Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study","abstract":"OBJECTIVE: This study was undertaken to evaluate the long-term safety and effectiveness of fenfluramine in patients with Lennox-Gastaut syndrome (LGS). METHODS: Eligible patients with LGS who completed a 14-week phase 3 randomized clinical trial enrolled in an open-label extension (OLE; NCT03355209). All patients were initially started on .2 mg/kg/day fenfluramine and after 1 month were titrated by effectiveness and tolerability, which were assessed at 3-month intervals. The protocol-specified treatment duration was 12 months, but COVID-19-related delays resulted in 142 patients completing their final visit after 12 months. RESULTS: As of October 19, 2020, 247 patients were enrolled in the OLE. Mean age was 14.3 ± 7.6 years (79 [32%] adults) and median fenfluramine treatment duration was 364 days; 88.3% of patients received 2-4 concomitant antiseizure medications. Median percentage change in monthly drop seizure frequency was -28.6% over the entire OLE (n = 241) and -50.5% at Month 15 (n = 142, p < .0001); 75 of 241 patients (31.1%) experienced ≥50% reduction in drop seizure frequency. Median percentage change in nondrop seizure frequency was -45.9% (n = 192, p = .0038). Generalized tonic-clonic seizures (GTCS) and tonic seizures were most responsive to treatment, with median reductions over the entire OLE of 48.8% (p < .0001, n = 106) and 35.8% (p < .0001, n = 186), respectively. A total of 37.6% (95% confidence interval [CI] = 31.4%-44.1%, n = 237) of investigators and 35.2% of caregivers (95% CI = 29.1%-41.8%, n = 230) rated patients as Much Improved/Very Much Improved on the Clinical Global Impression of Improvement scale. The most frequent treatment-emergent adverse events were decreased appetite (16.2%) and fatigue (13.4%). No cases of valvular heart disease (VHD) or pulmonary arterial hypertension (PAH) were observed. SIGNIFICANCE: Patients with LGS experienced sustained reductions in drop seizure frequency on fenfluramine treatment, with a particularly robust reduction in frequency of GTCS, the key risk factor for sudden unexpected death in epilepsy. Fenfluramine was generally well tolerated; VHD or PAH was not observed long-term. Fenfluramine may provide an important long-term treatment option for LGS.","journal":"Epilepsia","year":2022,"id":239355,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":50,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9531,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":154477,"name":"Ingrid E Scheffer","orcid":"0000-0002-2311-2174","position":1,"is_corresponding":false},{"id":323118,"name":"Berten Ceulemans","orcid":"0000-0001-7818-0679","position":2,"is_corresponding":false},{"id":724727,"name":"Joseph Sullivan","orcid":"0000-0003-2081-8988","position":3,"is_corresponding":false},{"id":864884,"name":"Katherine Nickels","orcid":"0000-0002-6579-3035","position":4,"is_corresponding":false},{"id":864885,"name":"Lieven Lagae","orcid":"0000-0002-7118-0139","position":5,"is_corresponding":false},{"id":52251,"name":"Renzo Guerrini","orcid":"0000-0002-7272-7079","position":6,"is_corresponding":false},{"id":236855,"name":"Sameer M. Zuberi","orcid":"0000-0002-4489-4697","position":7,"is_corresponding":false},{"id":494276,"name":"Rima Nabbout","orcid":"0000-0001-5877-4074","position":8,"is_corresponding":false},{"id":476255,"name":"Kate Riney","orcid":null,"position":9,"is_corresponding":false},{"id":267116,"name":"Anupam Agarwal","orcid":"0000-0003-4276-5186","position":10,"is_corresponding":false},{"id":864886,"name":"Michael Lock","orcid":"0000-0002-4179-9301","position":11,"is_corresponding":false},{"id":864887,"name":"David Dai","orcid":"0000-0001-9063-7774","position":12,"is_corresponding":false},{"id":865416,"name":"Gail Farfel","orcid":null,"position":13,"is_corresponding":false},{"id":864888,"name":"Bradley S. Galer","orcid":"0000-0002-4735-3327","position":14,"is_corresponding":false},{"id":864889,"name":"Arnold R. Gammaitoni","orcid":"0000-0002-4775-2862","position":15,"is_corresponding":false},{"id":865417,"name":"Shikha Polega","orcid":null,"position":16,"is_corresponding":false},{"id":864890,"name":"Ronald L. Davis","orcid":"0000-0003-3235-0032","position":17,"is_corresponding":false},{"id":864891,"name":"António Gil‐Nagel","orcid":"0000-0003-4515-0793","position":18,"is_corresponding":false},{"id":864883,"name":"Kelly G. Knupp","orcid":"0000-0002-1967-0827","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":null,"created_at":"2026-07-19T00:22:36.865157Z","pmid":"36196777","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}